Ascendis Pharma A/S
ASNDNext catalyst
TransCon IL-2 β/γ
Advanced Solid Tumor
Get an email about ASND's next catalysts
Track Ascendis Pharma A/S (ASND) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (Phase 2 readout).See the timeline
2 upcoming, 1 past
TransCon IL-2 β/γ Phase 2 Est. Readout (IL Believe)
Primary completion for TransCon IL-2 β/γ trial (NCT05081609) in Advanced Solid Tumor
SourceNavepegritide Phase 2 Est. Readout (teACH)
Primary completion for Navepegritide trial (NCT06732895) in Achondroplasia
SourceHow ASND's past catalysts played out
Market Overview
Stock performance and key metrics
Navepegritide (TransCon CNP)
Achondroplasia
TransCon hGH
Growth Hormone Deficiency, Pediatric
TransCon CNP
Achondroplasia
Once weekly subcutaneous injection of TransCon hGH
Growth Hormone Deficiency, Pediatric
Lonapegsomatropin
Growth Hormone Deficiency
Somatropin
Turner Syndrome
TransCon TLR7/8 Agonist
Advanced Solid Tumor
TransCon IL-2 β/γ
Advanced Solid Tumor
ACP-001 (TransCon hGH)
Adult Growth Hormone Deficiency
Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections
Achondroplasia
ACP-001
Growth Hormone Deficiency (GHD)
Navepegritide
Achondroplasia
Chemotherapy drug
Advanced Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Navepegritide (TransCon CNP) | Phase 3 | Achondroplasia | - | - |
TransCon hGH | Phase 3 | Growth Hormone Deficiency, Pediatric | - | - |
TransCon CNP | Phase 3 | Achondroplasia | - | - |
Once weekly subcutaneous injection of TransCon hGH | Phase 3 | Growth Hormone Deficiency, Pediatric | - | - |
Lonapegsomatropin | Phase 3 | Growth Hormone Deficiency | - | - |
Somatropin | Phase 2 | Turner Syndrome | - | - |
TransCon TLR7/8 Agonist | Phase 2 | Advanced Solid Tumor | - | - |
TransCon IL-2 β/γ | Phase 2 | Advanced Solid Tumor | - | - |
ACP-001 (TransCon hGH) | Phase 2 | Adult Growth Hormone Deficiency | - | - |
Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections | Phase 2 | Achondroplasia | - | - |
ACP-001 | Phase 2 | Growth Hormone Deficiency (GHD) | - | - |
Navepegritide | Phase 2 | Achondroplasia | - | - |
Chemotherapy drug | Phase 2 | Advanced Solid Tumor | - | - |
Achondroplasia
6 drugs in this indication
Growth Hormone Deficiency (GHD)
1 drug in this indication
Adult Growth Hormone Deficiency
1 drug in this indication
Growth Hormone Deficiency, Pediatric
1 drug in this indication
hypoparathyroidism
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Ascendis Pharma A/S's drug pipeline?→
CatalystAlert tracks 13 drug candidates in Ascendis Pharma A/S's (ASND) pipeline across Phase 3, Phase 2. Its lead program is Lonapegsomatropin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Ascendis Pharma A/S's next FDA catalyst?→
Ascendis Pharma A/S's (ASND) next tracked catalyst is a Phase 2 readout expected August 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ASND biotech catalysts?→
Add ASND to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ascendis Pharma A/S's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
